No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Asset Management - Global
This investment vehicle aims to precisely track the value of the Chinese Renminbi relative to the U.S. dollar. It provides both individual and institutional investors with a straightforward and economical way to gain exposure to China's currency, similar to directly owning the Renminbi. The fees for buying these shares are designed to be equivalent to, or no higher than, those for acquiring any other publicly traded stock.
No one on the platform currently holds FXCH.
No tracked institution reports a position in FXCH as of their last filing.
No one on the platform has traded FXCH yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Analyst estimates unavailable for this ticker.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| FXCHInvesco CurrencyShares Chinese Renminbi Trust | $69.69 | -0.08% | $3M | — |
| BUDXCannabis Growth ETF | $9.97 | -2.59% | $4M | — |
| EMGDSimplify Emerging Markets Equity PLUS Downside Convexity ETF | $16.70 | +0.29% | $4M | — |
| FHKFirst Trust Hong Kong AlphaDEX Fund | $34.58 | -0.79% | $3M | — |
| FXSGInvesco CurrencyShares Singapore Dollar Trust | $70.23 | -0.22% | $3M | — |
| HYLGGlobal X Health Care Covered Call & Growth ETF | $24.54 | +0.00% | $3M | — |
| MSUSLHA Market State Tactical U.S. Equity ETF | $22.91 | -0.13% | $3M | — |
Source: Financial Modeling Prep · peers by sector/industry
The investment seeks to reflect the price in USD of the Chinese Renminbi. The Shares are intended to provide institutional and retail investors with a simple, cost-effective means of gaining investment benefits similar to those of holding Chinese Renminbi. The costs of purchasing Shares should not exceed the costs associated with purchasing any other publicly-traded equity securities.
No constituent disclosure available for this fund yet.